The complaint

Prytime Medical Devices, Inc. v. Front Line Medical Technologies, Inc., No. 6:26-cv-00728 (W.D. Tex., Waco Division), is an 11-page complaint filed November 17, 2026, as ECF No. 1, with a jury demand. The complaint describes Prytime as a Delaware corporation with its principal place of business in Boerne, Texas. It alleges, on information and belief, that Front Line is a Canadian corporation with a principal place of business in Toronto, Ontario, Canada. A docket assignment entry dated November 17, 2026, assigns the case to District Judge Leon Schydlower.

Count I is for infringement of U.S. Patent No. 12,797,578. Count II is for unfair competition and false advertising under section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a). The complaint states that the two companies compete in the United States market for REBOA catheter systems.

The patent and the accused product

The '578 patent is titled Occlusion Catheter System for Partial Occlusion or Full Occlusion. It issued on November 17, 2026, the same day the complaint was filed, on Application No. 19/356,360, filed October 13, 2025. The complaint states that Prytime possesses all rights of recovery under the patent, including the right to sue for infringement.

The accused product is Front Line's COBRA-OS Device, which the complaint describes as an aortic occlusion device. On information and belief, including from Front Line's website, the complaint alleges that Front Line makes, sells, and/or imports the device into the United States, and that Front Line has obtained FDA clearance and sells and/or imports the device into the United States for temporary occlusion of large vessels, including in patients requiring emergency control of hemorrhage and/or circulatory support.

The complaint asserts at least claims 1, 2, 4, 5, 7-15, 17, and 19-25 of the '578 patent. It alleges, on information and belief, that Front Line is infringing those claims, literally or under the doctrine of equivalents, by offering to sell the COBRA-OS Device without license or authority, and that Front Line will continue to infringe through making, using, selling, and/or importing the device into the United States. It points to a claim chart attached as Exhibit B. The complaint states that, as of November 17, 2026, the date the complaint was filed and the date Prytime demanded that Front Line cease and desist from infringing activity, Front Line has knowledge of the '578 patent and of its infringement. On information and belief, the complaint says Front Line has infringed the claims of the '578 patent and that its infringement will be willful if it continues to make, use, sell, and/or import the accused product into the United States.

What the patent covers

U.S. Patent 12,797,578 describes an occlusion catheter system for at least partial occlusion of a vessel. The system includes a proximal hub with an inflation connection and pathway, an inflation catheter member, an occlusion balloon, and a distal catheter member with an atraumatic tip that has a substantially circular profile in one configuration. In an uninflated condition, the balloon, the inflation catheter member, and the distal catheter member have a greatest outer diameter of less than 7 Fr. See U.S. Patent 12,797,578.

Asserted claims: 1, 2, 4, 5, 7-15, 17, and 19-25. Claim 1 covers an occlusion catheter system for partial or complete occlusion of the aorta, with a proximal hub that forms an internal inflation fluid pathway, a manually actuated flow valve proximal to an inlet of that hub and connected to it, actuatable into a first position that provides bi-directional fluid communication between an inflation device and the inflation pathway, a proximal catheter member, a distal catheter member, a compliant occlusion balloon between them that can be inflated with a liquid when placed in the aorta and that has a proximal neck, a distal neck, and a body, and a stiffener whose proximal end is located within and fixedly coupled to the hub, that otherwise runs uncoupled in the proximal catheter member, and that extends into and beyond the balloon's body.

Claim 2 covers the system of claim 1 with a lumen from the hub through the proximal catheter member into the balloon, and it requires the stiffener to be longitudinally solid throughout its run in the proximal catheter member and into and beyond the balloon body. Claim 4 covers the system of claim 1 in which the proximal end of the stiffener is bonded to the proximal hub, and claim 5, which depends from claim 4, requires that the bond be adhesive. Claim 7 covers the system of claim 1 in which the flow valve can also be moved to a second position that blocks fluid communication between the inflation device and the inflation pathway, with the stiffener extending within the proximal catheter member. Claims 8, 9, and 10 cover the system of claim 1 in which the proximal catheter member, the balloon, and the distal catheter member have a greatest uninflated outer diameter of 8 Fr or less, 7 Fr or less, or 6 Fr or less, respectively. Claim 11 covers the system of claim 1 in which the stiffener is constructed of a metal.

Claim 12 covers an occlusion catheter assembly that includes the system of claim 1 and the inflation device, which is configured to connect to the hub's inflation pathway through the flow valve and to deliver the liquid inflation medium to inflate the balloon, when the balloon is in the aorta, to at least partially occlude the aorta. Claim 13 covers the assembly of claim 12 in which the inflation device is a manually actuated syringe.

Claim 14 covers an occlusion catheter system for partial or complete occlusion of the aorta to preserve blood flow to a patient's heart and brain. It requires a proximal hub with a single inlet and an internal inflation pathway, a manually actuated flow valve, a proximal catheter member in fluid communication with that pathway, a distal catheter member, a compliant occlusion balloon between them, a lumen from the hub through the proximal catheter member into the balloon, and a stiffener whose proximal end is located within and bonded to the hub, is otherwise uncoupled within that lumen, and is spaced distally from the flow valve, with the stiffener's distal end extending into the distal catheter member. In a first valve position, the valve provides bi-directional fluid communication through the single inlet for balloon inflation and deflation; in a second position, that communication is blocked; and the valve can be moved into each of those positions with the stiffener extending distally from the proximal catheter member. Claim 15 covers the system of claim 14 in which the proximal end of the stiffener is adhesively bonded to the hub. Claim 17 covers the system of claim 14 in which the stiffener is longitudinally solid from its proximal end to its distal end.

Claim 19 covers the system of claim 14 in which the proximal and distal catheter members are tubular and the proximal catheter member, the balloon, and the distal catheter member have a greatest uninflated outer diameter of 8 Fr or less. Claim 20 covers the same arrangement with a greatest uninflated outer diameter of 6 Fr or less. Claim 21 covers the system of claim 14 in which the proximal and distal catheter members are constructed of a polymeric material, and the balloon's proximal and distal ends are attached to those members respectively.

Claim 22 covers an assembly that includes the system of claim 14 and the inflation device, configured to connect to the hub's inflation pathway through the flow valve and to deliver liquid through the flow valve to inflate the balloon in the aorta to at least partially occlude the aorta. Claim 23 covers the assembly of claim 22 and states that the bonding of the stiffener's proximal end to the hub provides stiffness for the system to resist pressure that builds against it during occlusion of the aorta. Claim 24 covers the assembly of claim 22 in which the inflation device is a manually actuated syringe.

Claim 25 covers an occlusion catheter system for partial or complete occlusion of the aorta to occlude non-compressible hemorrhage in emergency or trauma environments where guidance imaging is typically not available. It requires a proximal hub with an internal inflation pathway, a manually actuated flow valve connected to an inlet of the hub and actuatable into a first position that provides bi-directional fluid communication between a syringe and that pathway, a proximal catheter member, a distal catheter member that ends in an atraumatic tip, a compliant occlusion balloon between them, a length marking on the exterior of the proximal catheter member to indicate insertion depth, an inflation lumen from the hub through the proximal catheter member into the balloon, and a stiffener that is longitudinally solid from end to end, that extends within the inflation lumen, the balloon, and into the distal catheter member, whose proximal end is located within and fixedly coupled to the hub and is otherwise uncoupled within the inflation lumen, and whose distal end extends into the distal catheter member, with a greatest uninflated outer diameter of 6 Fr or less for the proximal catheter member, the balloon, and the distal catheter member.

The Lanham Act claim

The complaint says Prytime's pREBOA-PRO Catheter is cleared by the United States Food and Drug Administration for "temporary partial or complete occlusion of large vessels," and it calls that catheter the first and only catheter FDA-cleared for partial REBOA, citing FDA 510(k) No. K243795. It says Front Line's COBRA-OS Device is cleared only for "temporary occlusion of large vessels" or full temporary occlusion of large vessels, citing FDA 510(k) No. K201652. On information and belief, the complaint alleges that Front Line has not obtained FDA clearance to market the COBRA-OS Device for partial occlusion of the aorta, which it calls partial REBOA.

The complaint alleges that Front Line nonetheless promotes the COBRA-OS Device to U.S. purchasers for partial REBOA. It quotes a video on Front Line's YouTube channel titled "Front Line Medical Technologies Inc. | COBRA-OS Educational Video" as instructing clinicians, for "partial reboa purposes," to remove 0.2 to 0.4 cc's at a time. It also quotes Front Line's website as stating that the "COBRA-OS can do Partial REBOA too!" and that an "[i]nnovative balloon design allows for partial REBOA and controlled deflation," while advertising that the device is available in the United States with "FDA Clearance." The complaint calls these the Partial REBOA Statements, and it alleges that they are commercial advertising in interstate commerce that is literally false or at least misleading, because they represent that the device is designed for, capable of safely performing, and FDA-cleared for partial REBOA.

It alleges that those statements have deceived, or have a tendency to deceive, a substantial segment of potential consumers, and that the deception is material because partial occlusion capability is an important purchasing consideration and distinguishes the pREBOA-PRO Catheter from competing devices. It alleges injury through diverted sales and lost goodwill, and, on information and belief, that Front Line's conduct is willful because Front Line knows the scope of its own FDA clearance. The count is pleaded under 15 U.S.C. § 1125(a)(1)(B).

The earlier '737 patent case

The complaint states that Front Line has been aware of Prytime's patents directed to REBOA catheter systems since at least January 2024, when Prytime sued Front Line for infringement of U.S. Patent No. 11,857,737, which it describes as being in the same patent family as the '578 patent. It cites Prytime Medical Devices, Inc. v. Front Line Medical Technologies, Inc., No. 6:24-cv-00001-RP (W.D. Tex. filed Jan. 2, 2024). The docket in that earlier case lists a March 9, 2026 entry labeled "Order AND Order Staying Case."

Jurisdiction, venue, and the prayer

The complaint invokes jurisdiction under 28 U.S.C. §§ 1331 and 1338(a) and (b), and 15 U.S.C. § 1121. It alleges that the court has personal jurisdiction because, on information and belief, Front Line uses, markets, and/or sells the COBRA-OS Device in Texas and derives revenue from the use and/or sale of the device in Texas. In the alternative, on information and belief, it invokes Federal Rule of Civil Procedure 4(k)(2). It alleges venue under 28 U.S.C. § 1391(c)(3) because Front Line is a foreign corporation not residing in any state in the United States.

The prayer seeks a judgment of infringement; damages adequate to fully compensate Prytime for infringement from the first use, manufacture, sale, offer for sale, or importation of the COBRA-OS Device on or after the filing date through the expiration of the '578 patent, together with prejudgment interest and costs; a finding that infringement was willful on or after the filing date and enhancement of damages under 35 U.S.C. § 284; a permanent injunction against infringement of the '578 patent; a judgment that Front Line has engaged in unfair competition and false advertising in violation of section 43(a) of the Lanham Act; a permanent injunction under 15 U.S.C. § 1116 against representing that the COBRA-OS Device is designed, suitable, or FDA-cleared for partial REBOA, and requiring corrective advertising; Front Line's profits, Prytime's damages, and costs under 15 U.S.C. § 1117(a); and a finding that the case is exceptional under 35 U.S.C. § 285 and 15 U.S.C. § 1117(a), with an award of reasonable attorneys' fees; and such other and further relief as the court deems just and proper.

What to watch next

Watch for an answer or a Rule 12 motion. The case can end at any time, including by settlement or voluntary dismissal.